
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Bloss to serve on Astellas US Management Committee - NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced...
Read more about Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas
NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an...
Read more about Astellas Pharma US, Inc. reaches agreement with U.S. Department of Justice
The National Kidney Foundation (NKF) announced today, during National Donate Life Month, that Astellas Pharma US, Inc. was named the first-ever National Presenting Sponsor for the Kidney Walk....
The American Urological Association (AUA) and Astellas US LLC, a U.S. affiliate of Tokyo-based Astellas Pharma Inc., have announced a $3 million commitment to the Urology Care Foundation and to...
-- If isavuconazole is approved for invasive mucormycosis, QIDP status provides a five-year extension of market exclusivity -- NORTHBROOK, Ill., Feb. 27, 2014 /PRNewswire/ -- Astellas Pharma...